Terms: = Prostate cancer AND TBL1XR1, C21, 79718, TBLR1, IRA1, FLJ12894, DC42 AND Treatment
13 results:
1. Steroid 17α-hydroxylase/17, 20-lyase (cytochrome P450 17A1).
Guengerich FP; McCarty KD; Tateishi Y; Liu L
Methods Enzymol; 2023; 689():39-63. PubMed ID: 37802581
[TBL] [Abstract] [Full Text] [Related]
2. miR-199a/214 cluster enhances prostate cancer sensitiveness to nimotuzumab via targeting tbl1xr1.
Hu S; Zhou Q; Lu Q; Guo X; Wang Y; Duan YX
Kaohsiung J Med Sci; 2023 Dec; 39(12):1178-1189. PubMed ID: 37772770
[TBL] [Abstract] [Full Text] [Related]
3. Comprehensive biomarker profiles and chemometric filtering of urinary metabolomics for effective discrimination of prostate carcinoma from benign hyperplasia.
Amante E; Cerrato A; Alladio E; Capriotti AL; Cavaliere C; Marini F; Montone CM; Piovesana S; Laganà A; Vincenti M
Sci Rep; 2022 Mar; 12(1):4361. PubMed ID: 35288652
[TBL] [Abstract] [Full Text] [Related]
4. 37-year incidence and mortality time trends of common cancer types by sex, age, and stage in the canton of Zurich.
Wanner M; Matthes KL; Karavasiloglou N; Limam M; Korol D; Rohrmann S
Swiss Med Wkly; 2020 Dec; 150():w20388. PubMed ID: 33378540
[TBL] [Abstract] [Full Text] [Related]
5. Suppressed Sex Hormone Biosynthesis by Alkylresorcinols: A Possible Link to Chemoprevention.
Oskarsson A; Ohlsson Andersson Å
Nutr Cancer; 2016; 68(6):978-87. PubMed ID: 27352233
[TBL] [Abstract] [Full Text] [Related]
6. SUMOylation of TBL1 and tblr1 promotes androgen-independent prostate cancer cell growth.
Park SY; Na Y; Lee MH; Seo JS; Lee YH; Choi KC; Choi HK; Yoon HG
Oncotarget; 2016 Jul; 7(27):41110-41122. PubMed ID: 27129164
[TBL] [Abstract] [Full Text] [Related]
7. Synthesis and biological activity of two pregnane derivatives with a triazole or imidazole ring at C-21.
Silva-Ortiz AV; Bratoeff E; Ramírez-Apan MT; García-Becerra R; Ordaz-Rosado D; Noyola-Martínez N; Castillo-Bocanegra R; Barrera D
J Steroid Biochem Mol Biol; 2016 May; 159():8-18. PubMed ID: 26924581
[TBL] [Abstract] [Full Text] [Related]
8. Expression and role of the angiotensin II AT2 receptor in human prostate tissue: in search of a new therapeutic option for prostate cancer.
Guimond MO; Battista MC; Nikjouitavabi F; Carmel M; Barres V; Doueik AA; Fazli L; Gleave M; Sabbagh R; Gallo-Payet N
Prostate; 2013 Jul; 73(10):1057-68. PubMed ID: 23389987
[TBL] [Abstract] [Full Text] [Related]
9. Proline-mediated proteasomal degradation of the prostate-specific tumor suppressor NKX3.1.
Rao V; Guan B; Mutton LN; Bieberich CJ
J Biol Chem; 2012 Oct; 287(43):36331-40. PubMed ID: 22910912
[TBL] [Abstract] [Full Text] [Related]
10. Inhibitory effect of synthetic progestins, 4-MA and cyanoketone on human placental 3 beta-hydroxysteroid dehydrogenase/5----4-ene-isomerase activity.
Takahashi M; Luu-The V; Labrie F
J Steroid Biochem Mol Biol; 1990 Oct; 37(2):231-6. PubMed ID: 2268554
[TBL] [Abstract] [Full Text] [Related]
11. Endocrine effects of combined treatment with an LHRH agonist in association with flutamide in metastatic prostatic carcinoma.
Bélanger A; Labrie F; Dupont A; Brochu M; Cusan L
Clin Invest Med; 1988 Oct; 11(5):321-6. PubMed ID: 2972431
[TBL] [Abstract] [Full Text] [Related]
12. Pharmacological studies on androgen suppression in therapy of prostate carcinoma.
Sandow J; von Rechenberg W; Engelbart K
Am J Clin Oncol; 1988; 11 Suppl 1():S6-10. PubMed ID: 3291602
[TBL] [Abstract] [Full Text] [Related]
13. Endocrine effects of high-dose ketoconazole therapy in advanced prostatic cancer.
Heyns W; Drochmans A; van der Schueren E; Verhoeven G
Acta Endocrinol (Copenh); 1985 Oct; 110(2):276-83. PubMed ID: 3933237
[TBL] [Abstract] [Full Text] [Related]
